... alone. Dynavax is a stock worth watching closely - my price target would be ~$15... last year, I set a price target of $18 for Dynavax stock - or a firm valuation... my last note, and the stock price has climbed from $5.5, ... Johnson (JNJ) and AstraZeneca's (AZN) adenoviruses in the market, plus ... that my calculated fair value price for Dynavax stock of $15 is justified by ...

... at a ~$76/ share stock price and I would expect a... J&J. This $76 stock price would require that the FDA...), that would correspond to a stock price of ~$24/ share, minimum, ...sell just before the stock took off. It’s possible ... towards Merck, J&J, AZN, and possibly a consortium in ...work through the cooperation of AZN, DoD, INO, and others might... have never shorted a stock but I’m considering shorting ...

... at a ~$76/ share stock price and I would expect a... J&J. This $76 stock price would require that the FDA...), that would correspond to a stock price of ~$24/ share, minimum, ...sell just before the stock took off. It’s possible ... towards Merck, J&J, AZN, and possibly a consortium in ...work through the cooperation of AZN, DoD, INO, and others might... have never shorted a stock but I’m considering shorting ...

...):- Compute 2.1243 x AZN share price at the close on... tax. Your basis in the AZN stock is another calculation and you ... above plus appreciation of the AZN stock since the merger.

...):- Compute 2.1243 x AZN share price at the close on... tax. Your basis in the AZN stock is another calculation and you ... above plus appreciation of the AZN stock since the merger.

...a background of a share price that lately has trended ... Inovio is partnered with AstraZeneca (AZN) for MEDI0457 for HPV caused...to a rise in the stock price. Milestones from current partnerships or ...expansion or a higher list price) per year for VGX-3100,...see its market capitalization and stock price more than double by, say, ...then label expansion. At current price, I believe upside potential outweighs ...

...a background of a share price that lately has trended ... Inovio is partnered with AstraZeneca (AZN) for MEDI0457 for HPV caused...to a rise in the stock price. Milestones from current partnerships or ...expansion or a higher list price) per year for VGX-3100,...see its market capitalization and stock price more than double by, say, ...then label expansion. At current price, I believe upside potential outweighs ...

I would love to talk to O'Day and ask him why the stock has gone nowhere since he got there. I bet that would be some answer. I'm sure, in his mind, it's not his fault. Right. The stock price is how you keep score Mr. O'Day. Why didn't you sell to AZN when they came courting? $100?

I would love to talk to O'Day and ask him why the stock has gone nowhere since he got there. I bet that would be some answer. I'm sure, in his mind, it's not his fault. Right. The stock price is how you keep score Mr. O'Day. Why didn't you sell to AZN when they came courting? $100?

..., and remember that AstraZeneca (ticker: AZN), which is listed in London... company's bottom line and stock price higher in the coming years...

..., and remember that AstraZeneca (ticker: AZN), which is listed in London... company's bottom line and stock price higher in the coming years...

...close to the price of J&J’s adenovirus vaccine. However, AZN’s efficacy of...The Guardian, Barclays Interestingly, besides AZN's vaccine, NVAX’s vaccine ... India, has licensed both AZN’s and NVAX’s vaccines ...likely cost more than the AZN’s not-for-profit vaccine, ...around the $150 price level, that attracted strong buying interest previously, while we also expect the stock to consolidate somewhere between...

...close to the price of J&J’s adenovirus vaccine. However, AZN’s efficacy of...The Guardian, Barclays Interestingly, besides AZN's vaccine, NVAX’s vaccine ... India, has licensed both AZN’s and NVAX’s vaccines ...likely cost more than the AZN’s not-for-profit vaccine, ...around the $150 price level, that attracted strong buying interest previously, while we also expect the stock to consolidate somewhere between...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...

... to resist the pressure of price-based competition," wrote SVB Leerink ... an April 28 note. The stock closed Wednesday at $248.63. ..., analysts remain positive on the stock. Of the 22 tracked by ... 20 analysts who cover the stock tracked by FactSet, 13 rate ... acquired by AstraZeneca (AZN) for a total consideration worth $175 per share. The stock is now trading at that price. AstraZeneca says that...